- Date 23 July 2014
- Documents : 4
- History
- (Restricted access link)
Listen
SALAZOPYRINE
RHEUMATOLOGY - Focus
Opinions on drugs -
Posted on
Feb 25 2015
Reason for request
Renewal of inclusion
Non-biologic DMARDs in rheumatoid arthritis (excluding methotrexate and leflunomide)
Azathioprine, sulfasalazine and synthetic antimalarials (hydroxychloroquine, chloroquine) still have a substantial clinical benefit.
Cyclosporine, D-penicillamine, gold salts and tiopronin have no longer a clinical benefit relative to the available alternatives.
- The main focus concerns the following disease-modifying treatments for rheumatoid arthritis (RA):
- azathioprine (IMUREL)
- chloroquine (NIVAQUINE)
- cyclosporine (NEORAL, SANDIMMUN)
- D-penicillamine (TROLOVOL)
- hydroxychloroquine (PLAQUENIL)
- gold salts (ALLOCHRYSINE)
- sulfasalazine (SALAZOPYRINE)
- tiopronin (ACADIONE)
- According to current recommendations, the opinion of the French Society of Rheumatology and the published clinical data, azathioprine, sulfasalazine and synthetic antimalarials (hydroxychloroquine, chloroquine) still have a role in the therapeutic strategy for RA.
- Cyclosporine, D-penicillamine, gold salts and tiopronin no longer have a role in this therapeutic strategies.
Clinical Benefit
| Substantial |
The actual benefit of this medicinal product remains substantial In the treatment of RA. Ulcerative colitis the actual benefit of this medicinal product remains substantial in this indication. |
| Moderate |
The actual benefit of SALAZOPYRINE remains moderate in the induction and maintenance treatment of Crohn's disease.
|
